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Background: Anti-psychotics, prescribed to people with dementia, are associated with approximately 1,800 excess
annual deaths in the UK. A key public health objective is to limit such prescribing of anti-psychotics.
Methods: This project was conducted within primary care in Medway Primary Care Trust (PCT) in the UK. There
were 2 stages for the intervention. First, primary care information systems including the dementia register were
searched by a pharmacy technician to identify people with dementia prescribed anti-psychotics. Second, a trained
specialist pharmacist conducted targeted clinical medication reviews in people with dementia initiated on
anti-psychotics by primary care, identified by the data search.
Results: Data were collected from 59 practices. One hundred and sixty-one (15.3%) of 1051 people on the
dementia register were receiving low-dose anti-psychotics. People with dementia living in residential homes were
nearly 3.5 times more likely to receive an anti-psychotic [25.5% of care home residents (118/462) vs. 7.3% of people
living at home (43/589)] than people living in their own homes (p < 0.0001; Fisher’s exact test). In 26 practices there
was no-one on the dementia register receiving low-dose anti-psychotics.
Of the 161 people with dementia prescribed low-dose anti-psychotics, 91 were receiving on-going treatment from
local secondary care mental health services or Learning Disability Teams. Of the remaining 70 patients the
anti-psychotic was either withdrawn, or the dosage was reduced, in 43 instances (61.4%) following the
pharmacy-led medication review.
Conclusions: In total 15.3% of people on the dementia register were receiving a low-dose anti-psychotic. However,
such data, including the recent national audit may under-estimate the usage of anti-psychotics in people with
dementia. Anti-psychotics were used more commonly within care home settings. The pharmacist-led medication
review successfully limited the prescribing of anti-psychotics to people with dementia.
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Dementia has an estimated global prevalence of 35 mil-
lion individuals [1]. In the UK 700,000 people live with
dementia - a figure which will double over the next
30 years, reflecting global predictions [1-3]. Whilst BPSD
(behavioural and psychological symptoms of dementia)
are very common, both the point prevalence, the propor-
tion having symptoms at any one time point, and the cu-
mulative risk are unclear. A recent study concluded that
BPSD affect nearly everyone with dementia [4]. Whereas
the Cochrane review simply stated that 50% of people* Correspondence: i.maidment@aston.ac.uk
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reproduction in any medium, provided the orwith dementia experience such symptoms [5]. Other
studies have estimated the point prevalence between
60% and 80%, and the cumulative risk during the course
of the illness at 90% [6].
BPSD are among the most difficult symptoms to treat,
a primary source of caregiver stress, strongly associated
with carer burden and depression and one of the main
drivers for placement breakdown and admission to resi-
dential care facilities [7-12]. Behavioural symptoms have
traditionally been treated with anti-psychotics, however
their usage is implicated in approximately 1,800 annual
deaths [2]. Recently the National Dementia Strategy
(NDS) targeted a two-thirds reduction in such usage of
anti-psychotics [2,13-15]. However, there is limitedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dementia and the NDS estimated that, as a conservative
figure, up to 25% of people with dementia are likely to
be receiving anti-psychotics [2]. Due to the lack of data,
one of the initial recommendations of the NDS was to
obtain baseline data on the extent of anti-psychotic
usage [2]. Following collection of baseline data a target
for the size and speed of the reduction should be set; the
NDS also highlighted the potential role of pharmacists
in improving medication management and limiting the
inappropriate use of anti-psychotics in people with de-
mentia [2,14,16].
Method
Setting
This pharmacy-led program was conducted within Gen-
eral Practitioner (GP) surgeries in Medway Primary Care
Trust (PCT). Medway PCT covers the Medway towns in
Kent with a total population of 256,700 and a 60 plus
population of 51,500 [17]. Medway is a relatively
deprived area, ranked 132rd most deprived of 325 UK
boroughs in the 2010 Index of Deprivation, with pockets
of significant deprivation; eight geographical units called
‘Super Output Areas’ (SOAs) were ranked in the 10%
most deprived nationally [18].
Pharmaceutical support within Medway PCT is pro-
vided by a medication management team containing
pharmacists, pharmacy technicians and support staff; the
team has a history of a close working relationship with
GPs and undertaking clinical projects within individual
practices. Following the publication of the NDS one of
the key strategic priorities of the PCT was to limit the
prescribing of anti-psychotics to people with dementia.
This project, which was conducted from January to De-
cember 2011, had two aspects. First, in line with the
NDS, data were collected on anti-psychotic usage to
identify people on the dementia register within Medway
PCT prescribed anti-psychotics. Second, a specialist
pharmacist intervened in an appropriate cohort of
people with dementia commenced on anti-psychotics by
primary care identified by the data search.
Patient identification
Every practice information system, both the electronic
and paper format, was searched, by an experienced phar-
macy technician to identify people with dementia cur-
rently prescribed a low dose anti-psychotic, on acute or
repeat prescription. Dementia registers were established
within the UK as part of the Quality Outcome Frame-
work (QOF) – an incentive scheme to reward good
practice in primary care - to record people with demen-
tia within the practice [19,20]. The registers were estab-
lished within Medway PCT in 2006/07 and were used to
identify people with a confirmed diagnosis of dementia.The individual patient record including the medication
history of every person on the dementia register was
then searched to identify people prescribed low-dose
anti-psychotics. Initially, this was restricted to the 6
most commonly prescribed anti-psychotics based on
ePACT (electronic Prescribing Analysis and Cost Tabu-
lation) data. However, to ensure completeness, patient’s
notes were hand searched to identify other, less fre-
quently prescribed, anti-psychotics. For the six most
commonly prescribed anti-psychotics, low dose was
defined a priori (olanzapine up to 10 mg daily, risperi-
done up to 2 mg daily, quetiapine up to 100 mg daily,
amisulpiride up to 50 mg daily, sulpiride up to 200 mg
daily and haloperidol up to 1.5 mg daily). For the other
less frequently prescribed anti-psychotics the standard
British National Formulary (BNF) dosing schedules were
used to inform the decision on whether the dose was
low [21].
Finally, the document storage system, where key docu-
ments such as referral letters are stored, was searched to
determine where treatment was commenced (primary
care, secondary care mental health trust, acute trust or
Learning Disability Team). If the anti-psychotic had been
initiated by a secondary care organisation, the patient
was not included in the medication review, because the
anti-psychotic may have been used for under-lying
psychosis or a complex mental health problem. The resi-
dential status (living at home or in a care home) was also
collected.
Pharmacist-led medication review
After the cohort of people with dementia on long-term
anti-psychotics initiated by primary care was identified,
the intervention was delivered. Practices were ranked
according to the frequency of prescribing to prioritise
where the intervention should be delivered. The pharma-
cist delivering the intervention sent a copy of a report to
the GP, which identified the cohort of people with demen-
tia where anti-psychotic withdrawal should be attempted
and that the pharmacist was able to give support to the
GP in the process by providing advice on a suitable with-
drawal scheme, advising on local and national guidance
and linking with the care home [14,22-24]. This initial
communication was followed up either verbally or in
writing.
The pharmacist collaborated with the GP in identify-
ing, where withdrawal was potentially suitable and the
level of pharmacy support including whether a
pharmacist-led medication review, was required. Medi-
cation was withdrawn for clinical, not research reasons.
Hence, consent was not required. All participants
received usual care and any decision to alter medication
was made by the GP based on individual clinical needs,
following the pharmacist-led review. Withdrawal was
Number of people on the 
dementia register receiving low-
dose anti-psychotics initiated by 
primary care (n=70)
Number of people in whom the 
anti-psychotic was withdrawn or 
the dosage reduced (n=43)
Number of people on the 
dementia register (n=1051)
Number of people on the 
dementia register receiving low-
dose anti-psychotics (n=161)
Figure 1 Intervention Flow chart.
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ondary care services, was receiving an anti-psychotic for
non-acute behavioural problems, and the anti-psychotic
had not been reviewed in the previous 12 months.
The clinical medication review (based on modified Na-
tional Prescribing Centre Level 3 medication review cri-
teria) was delivered by an experienced senior clinical
PCT pharmacist, who had a further qualification in de-
mentia with full access to medical and care home notes
[25]. The review included an individual withdrawal plan,
which took into account the length of time the person
had been on the anti-psychotic. In general the dose was
gradually reduced usually by 50% every two to four
weeks following discussions with the prescriber. During
the withdrawal patients continued to be monitored, fol-
lowed up, and treated by their own physicians according
to their individual clinical needs. Care home staff were
encouraged to log behaviours using ABC (Antecedents,
Behaviour, Consequences) charts and monitor residents
for any change in general health [23].
Care staff discussed the project with next-of-kin and
whenever possible the person with dementia; if required
the pharmacist supported these discussions. Any deci-
sions from these discussions incorporated the views of
the person with dementia, next–of-kin and professional
carers. The pharmacist also provided support and train-
ing to the care home, which was designed to help staff
manage BPSD, and was available for further advice and
follow-up. The training utilised treatment guidelines for
use in primary care to treat BPSD that were developed
by a multi-disciplinary team of clinicians from the local
mental health trust and local PCTs [23]. The overall
concept of the training was based upon a person-
centred approach including the need to understand the
causes of any behaviour and accurately record any be-
haviour, non-pharmacological treatments options, and
the appropriate pharmacological management of behav-
ioural problems in dementia [22,23].
This project was approved by Medway PCT. Ethics
committee approval was not required because the pro-
ject was a service evaluation and data were collected to
evaluate this new service and not for the purposes of re-
search. The decision to publish was made retrospectively
and individual patient data was not identifiable to any-
one in the team (IM, CF) conducting the secondary ana-
lysis of the results for publication.
Results
See Figure 1 for a diagrammatical representation of the
results.
Anti-psychotic usage
Data were collected from 59 out of 60 (98.3%) practices
(or groups of practices) within Medway PCT; onepractice declined to take part. There were 1051 people
on the dementia register in the 59 practices; of these 462
were in residential care and 589 lived in their own home.
In total 161 people on the dementia register were receiv-
ing low-dose anti-psychotics; of these 118 were in resi-
dential care and 43 lived in their own home. People with
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times more likely to receive an anti-psychotic; 25.5%
(118/462) of people resident in care homes compared
with 7.3% (43/589) of people living in their own homes
(p < 0.0001; Fisher’s exact test) [26].
On average (mean value) each practice treated 2.77
(range – 0 to 26; +/− SD 4.88) people with dementia
with low-dose anti-psychotics. In 26 practices no-one
with dementia was receiving low-dose anti-psychotics.
Put another way, if one assumes that the dementia regis-
ter was accurate, approaching half (44.1%) of all prac-
tices in Medway PCT were not treating anyone with
dementia with a low-dose anti-psychotic. Five practices
accounted for over 50% (81/161) of the prescribing; 3 of
these 5 practices were significantly larger (16,575, 13,805
and 8,866) than the mean practice in Medway PCT of
4,683 patients (report generated from http://www.epact.
ppa.nhs.uk on the 13th April 2012). The remaining two
practices were responsible for large care homes.
The most commonly used anti-psychotic was amisul-
pride (52 out of 161; see Table 1 for full details of anti-
psychotics used).Pharmacist-led medication review
Of the 161 people on the dementia register prescribed low-
dose anti-psychotics, 87 were receiving on-going treatment
from local secondary care mental health services and 4
from the local Learning Disability Teams. The remaining
70 patients were included in the pharmacy led review. Dif-
ferent surgeries accessed different levels of pharmaceutical
support and in total, following the pharmacy-led interven-
tion, anti-psychotics were withdrawn, or the dosage of the
anti-psychotic was reduced, in 43 instances (61.4%). The
pharmacist directly liaised with 11 practices to withdrawTable 1 Details of low-dose anti-psychotics used in
people with dementia
Anti-psychotic N (%)
Amisulpride 52 (32.3%)
Risperidone 37 (23.0%)
Quetiapine 35 (21.7%)
Olanzapine 14 (8.7%)
Aripiprazole 8 (5.0%)
Haloperidol 7 (4.3%)
Chlorpromazine 2 (1.2%)
Flupentixol 2 (1.2%)
Benperidol 1 (0.6%)
Sulpride 1 (0.6%)
Trifluoperazine 1 (0.6%)
Zuclopenthixol 1 (0.6%)
Total number of anti-psychotics 161 (100%)anti-psychotics in 33 people (47.1%). In a further two prac-
tices, one which supported a specialist dementia home, six
patients identified during data collection were withdrawn
from anti-psychotics. In one further practice, which sup-
ported a large EMI (elderly mentally ill) home, the pharma-
cist developed and provided withdrawal schedules for four
patients.
Discussion
Over 15% of people on the dementia register were re-
ceiving low-dose anti-psychotics. This compares with
the NDS, which estimated a point prevalence of 25%
[14] and an observational study, involving a random
sample of GP practices across five primary care trusts,
which found that 26% of people with dementia were pre-
scribed anti-psychotics [27]. The recent national audit
calculated that in 2011, nationally 6.8% and within
Medway PCT 10.5% [Personal Communication with
Jonathan Hope] of people with dementia received an
anti-psychotic [3]. However, only 45.7% of GP practices
across England participated in the national audit due to
technical issues or insufficient resources for data ex-
traction [3]. Across Medway PCT 17.5% of practices
participated in the national audit compared with 98.3%
of practices in this project [3].
Both the national audit and this project relied upon
the accuracy of the dementia registers. However, in
many cases a formal diagnosis of dementia may not be
recorded [3]. A typical GP practice would contain be-
tween 12 to 20 people with dementia and between three
to five people with dementia on low-dose anti-psychotics
[14,28]. In this project 26 practices failed to report any-
one on the dementia register receiving low-dose anti-
psychotics. The dementia register was set-up in 2006/07
in Medway and should have been well-established. How-
ever, an Alzheimer’s Society national survey identified
significant under diagnosis; in Medway only 43.8% of the
expected number of people with dementia received a
diagnosis, which reflects the national picture [29]. This
confirms findings elsewhere e.g. NHS Dumfries and Gal-
loway estimated that the QOF dementia register only
contained 32.9% of the expected dementia population
[30]. Therefore, both the national audit and this project
may under-estimate the number of people with dementia
prescribed anti-psychotics.
To confirm the extent of the usage of anti-psychotics in
dementia, an alternative approach to solely relying on the
dementia register may be required. One such alternative
option would be to initially identify everyone aged over 65
on low-dose anti-psychotics. A priori criteria for a diagno-
sis of dementia including a prescription for a cognitive en-
hancer, in addition to presence on the dementia register,
could then be applied. This population identified by the
alternative approach should be compared to that identified
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tures the true magnitude of the issue used, as entry criteria
for any future intervention.
Prescribing was concentrated in a relatively small
number of practices and a person with dementia in a
residential home was nearly 3.5 times more likely to re-
ceive a low-dose anti-psychotic than someone with de-
mentia living in their own home. This confirms earlier
research, which highlighted that anti-psychotic use for
people with dementia in nursing homes was becoming
increasingly prevalent [31]. Therefore, to achieve max-
imum benefit, and in line with the NDS, and the ap-
proach adopted in this project, baseline data should be
used to target where the intervention is delivered [14].
The most commonly used anti-psychotic was amisul-
pride, followed by risperidone and quetiapine. These three
anti-psychotics were also identified by an expert group of
old age consultant psychiatrists as the most appropriate
treatments for challenging behaviour in dementia [32].
However, the efficacy of amisulpride for this indication is
unproven, and although there may be less harm associated
with quetiapine, there is no evidence that quetiapine is ef-
fective in people with dementia [22,33-35]. Furthermore,
neither amisulpride nor quetiapine are licensed to treat the
behavioural and psychological symptoms of dementia. The
licensed treatment, risperidone, which is recommended by
local and national guidelines, was only used in 23.0% of
instances [22,23]. Risperidone was one of the first anti-
psychotics highlighted by the Committee of Safety on Med-
icines to cause excess mortality and local and national
guidelines, which highlight that all anti-psychotics carry a
similar risk, appear not to have been fully communicated to
prescribers [24,32,36].
There are various limitations with the project in
addition to issues highlighted regarding the accuracy of
the dementia register. The project was solely conducted
within a single PCT, and whilst the PCT covered a very
mixed area, the results are not necessarily generalisable
to other locations. People initiated on anti-psychotics by
secondary care were excluded and a joint pharmacist
and GP review, linking with secondary care including
experts in the non-pharmacological management of
BPSD, might have a more significant impact in limiting
the inappropriate prescribing of anti-psychotics [31].
In the short-term, the pharmacy-led intervention reduced
the prescribing of anti-psychotics. However, the scope was
relatively limited, and excluded other psychotropics, which
might be used in place of anti-psychotics [37]. Further,
patients were not formally followed-up to determine
whether the anti-psychotic was stopped, or simply the dose
reduced. The symptoms of BPSD fluctuate and continuing
input is likely to be required. To demonstrate such a long-
term sustainable quality improvement one would require a
full-scale research project which was beyond the scope ofthis evaluation of a clinical service. An initial step would be
a pilot randomised controlled trial (RCT) of a specialist
pharmacist-led medication review of psychotropics based
upon guidelines from the Alzheimer’s Society [22]. Such a
pilot should include a health economic assessment. A posi-
tive pilot, and subsequent full trial, could inform future ser-
vice development.
Key Practice Implications
– Whilst initial data is encouraging further research is
required on the role of pharmacy-led interventions
to reduce the prescribing of anti-psychotics and
other psychotropics for people with dementia.
– Any intervention should focus on care homes where the
majority of anti-psychotic prescribing appears to occur.
– The accuracy of the dementia register in identifying
people with dementia prescribed low-dose anti-
psychotics is unclear.
– Audit data including the recent national audit may
under-estimate the usage of anti-psychotics in
people with dementia.
Conclusion
This project identified that within one PCT approxi-
mately 15% of people on the dementia register were re-
ceiving low-dose anti-psychotics. However, this may be
an under-estimate, because the dementia register may
not capture everyone with dementia. Anti-psychotics
were used much more commonly within care home set-
tings and the most commonly used anti-psychotic was
amisulpride. The project also identified that a
pharmacist-led review could successfully limit the pre-
scribing of anti-psychotics to people with dementia.
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